Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
  1. All Episodes
  2. Cell Therapies Drive Immune System in Cures for Solid Tumors and Blood Cancers with Alain Maiore Mnemo Therapeutics

Cell Therapies Drive Immune System in Cures for Solid Tumors and Blood Cancers with Alain Maiore Mnemo Therapeutics

Aug 2, 2021

Alain Maiore is the Co-Founder and CEO of Mnemo Therapeutics and has a mission to change the future of cell therapy.  The Mnemo platform EnfiniT is an integrated drug discovery engine that combines T-cell engineering technologies with greater target identification to transform the body's immune response to overcome currently incurable diseases.

Mnemo has just raised $90 million in a Series A round, the largest round to date in France.

Alain says, "I think our job is to make sure that whatever technology we put together, everyone that is in need of having access to these drugs gets access to these drugs. So it is our responsibility to combine the technologies and medical development and the manufacturing of these drugs so that we can size the necessity of financial performance and shoulder reward with accessibility to every patient. That responsibility is increasingly important in the world that is opening to us."

@MnemoTx #MnemoTherapeutics #EnfiniT #Cancer #BloodCancer #CellTherapies #SolidTumors #DrugTargeting #TCells #Immunetherapies #epigenetics #CarTCells

Mnemo-tx.com

Download the transcript here

Mnemo Therapeutics